Prestige Pilot - Phoenix Atherectomy and Stellarex DCB Clinical Investigation in Infrapopliteal Interventions

Peripheral Artery Disease (PAD) Clinical Trial

Official title:

Prestige Pilot - Phoenix Atherectomy and Stellarex DCB Clinical Investigation in Infrapopliteal Interventions

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03744572
• Other study ID #: ASL201801
• Status: Completed
• Start date: October 17, 2018
• Est. completion date: June 1, 2022

Study information

• Verified date: January 2023
• Source: Klinikum Arnsberg
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This pilot study is to investigate if a lesion preparation strategy with Phoenix atherectomy before DCB (drug coated balloon) usage in patients with PAD (peripheral artery disease) Rutherford Stage 4-5 and mild/moderate/severe calcium can improve outcomes including patency and limb salvage and evaluate safety and performance of the combination therapy

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: June 1, 2022
• Est. primary completion date: December 22, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients must be = 18 years of age.

2. Patients are male or, if female, are either not of childbearing potential or must have a negative pregnancy test done within 7 days prior-index procedure and effective contraception must be used during participation in the Clinical Investigation.

3. Patients who are mentally and linguistically able to understand the aim of the Clinical Investigation and to show sufficient compliance in following the Clinical Investigation Plan.

4. Patients must agree to return for all required post-index procedure follow-up visits.

5. Patients are able to verbally acknowledge an understanding of the associated risks, benefits, and treatment alternatives to therapeutic options of the Clinical Investigation. Patients, by providing their informed consent, agree to these risks and benefits as stated in the patient informed consent document.

6. Rutherford Class 4-5

7. = 70% stenosis infrapopliteal lesion by angio visual assessment (later correlated with IVUS)

8. Target vessel(s) reconstitute(s) at or above the ankle with inline flow to at least one patent pedal vessel (includes perforating peroneal branches to dorsalis pedis and plantar artery).

9. The target lesion must either be de-novo or restenotic (stenosis = 70% or occlusion by visual estimate). If the target lesion is restenotic, the prior PTA must have been done > 30 days prior-index procedure.

10. Treatment of multiple target lesions is allowed, as long as the composite target lesion length is = 27 cm and the target lesions can be treated with a maximum of 2 overlapping Investigational Devices.

11. Presence of clearly visible calcification in two views (both sides of vessel at the same location) evaluated angiographically- [OPTIONAL: Computerized tomography (CT) angio images may substitute to confirm distribution of calcium, if available as standard of care]

12. Length of calcium = 25 % of total lesion length or = 2 cm total length by angio visual assessment (later correlated with IVUS)

13. At least one target lesion that is = 2cm in length

Exclusion Criteria:

1. Patients with a known hypersensitivity or contraindication to aspirin, heparin, clopidogrel, or other anticoagulant/anti-platelet therapies, Paclitaxel (or analogs) or sensitivity to contrast media that cannot be adequately premedicated.

2. Patients with any contraindications as mentioned in the Instructions for Use (IFU) of the Investigational Device.

3. Patients with a life expectancy, from the Investigator's opinion, of less than 2 years.

4. Patients that are currently participating in other clinical investigations involving any investigational drug or device that may potentially confound the results of the Clinical Investigation, or that would limit the patient's compliance with the follow-up requirements of the Clinical Investigation.

5. Patients with a history of Myocardial Infarction (MI), thrombolysis or angina within 30 days prior-index procedure.

6. Patients with a history of major disabling stroke within 3 months prior index procedure.

7. Patients with any type of previous or planned surgical or interventional procedure within 15 days prior- and/or within 30 days post-index procedure.

8. Patients with a presence or history of severe renal failure (Glomerular Filtration Rate (GFR) = 30 ml/min).

9. Patients who have undergone prior vascular surgery of the index limb to treat atherosclerotic disease.

10. Patients with clinically significant aneurysmal disease of the iliac, femoral or popliteal artery and patients with a history of clinically significant abdominal aortic aneurysm.

11. Treatment of the contralateral limb during the same index procedure or within 30 days post-index procedure in order to avoid confounding complications.

12. Target vessel(s) reconstitute(s) below the ankle with no inline flow to at least one patent pedal vessel.

13. Subjects scheduled to undergo a planned major amputation

14. Prior stent placement in the target lesion(s)

15. Unsuccessful guidewire crossing

16. Subintimal guidewire placement (confirmed by IVUS, no subintimal placement is allowed)

17. Persistent inflow disease left untreated or unsuccessfully treated

18. Non ischemic ulcers and/or ulcers at or above the ankle

Related Conditions & MeSH terms

• Peripheral Arterial Disease
• Peripheral Artery Disease (PAD)

Locations

Country	Name	City	State
Germany	Vascular Center of Klinikum Hochsauerland	Arnsberg
Germany	Universitäts-Herzzentrum Bad Krozingen	Bad Krozingen
Germany	SRH Klinikum Karlsbad-Langensteinbach	Karlsbad
Germany	St Franziskus Hospital Münster	Münster
Germany	GRN Klinik Weinheim	Weinheim

Sponsors (1)

Lead Sponsor	Collaborator
Michael Lichtenberg, MD

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of target lesions with patency at 6 months	Patency defined as freedom from occluded target lesions (flow) verified by duplex ultrasound without re-intervention	6 months
Primary	Composite Safety; Number of patients with freedom from BTK major adverse limb events (MALE) and/or perioperative death (POD)	Freedom from BTK major adverse limb events (MALE) and/or perioperative death (POD)	30-days
Secondary	Number of patients with limb salvage	Limb salvage is defined as freedom from major amputation	6, 12, and 24 months
Secondary	Number of target lesions with patency as indicated by PSVR measurement	Patency defined as freedom from >50% restenosis in the target lesion as indicated by a duplex ultrasound peak systolic velocity ratio (PSVR) < 2.5 or by visual assessment of an angiogram with no clinically driven reintervention	6,12, and 24 months
Secondary	Number of target lesions with secondary patency	Secondary patency is defined as freedom from occluded target lesions (flow) verified by duplex ultrasound	6, 12 and 24 months
Secondary	Number of target lesions with procedural success	Procedural sucess is defined as achievement of a =30% Diameter Stenosis (DS) at the end of the procedure without MAEs as determined by angiographic core lab	at end of percutaneous revascularization index procedure
Secondary	Number of target lesions with technical success	Technical sucess is defined as achievement of a =30% Diameter Stenosis (DS) following Phoenix and DCB as determined by angiographic core lab	at end of percutaneous revascularization index procedure
Secondary	Number of target lesions with device success for Phoenix atherectomy	Device success is defined as achievement of a =50% Diameter Stenosis (DS) post-Phoenix without pre-dilatation and before DCB or any adjunctive therapy as determined by angiographic core lab	during percutaneous revascularization index procedure post-Phoenix and before DCB treatment
Secondary	Wound, Ischemia, foot Infection (WIfI) Classification on target limb		1, 6,12 and 24 months
Secondary	Ankle-Brachial Index (ABI)		1, 6,12 and 24 months
Secondary	Clinical success at follow-up,	improvement of at least one Rutherford class compared to the pre-procedure Rutherford classification	1, 6, 12 or 24 months
Secondary	Pain rating scale scores compared to Baseline	Pain in the legs during the last 24 h rated on a numerical scale from 0 (no pain) to 10 (worst possible pain)	1, 6, 12 or 24 months
Secondary	Walking Impairment Questionnaire (WIQ) score compared to Baseline	The total WIQ score is defined as sum of five subscores. A subscore is calculated as sum of a scale for each of five separate domains.	1, 6, 12 or 24 months
Secondary	Percentage of complete wound healing (complete epithelialization)		1, 6, 12 or 24 months
Secondary	correlation between IVUS metrics and angiographic core lab assessment	Core lab assessed correlation between IVUS metrics of true luminal diameter, actual % area stenosis, change in plaque area and luminal gain pre- and post-therapy, plaque shape and angiographic core lab assessment of pre- and post-percent diameter stenosis (%DS) and the extent of vascular calcification will be determined	pre- and at end of percutaneous revascularization index procedure
Secondary	Number of patients without Major Adverse Event (MAE)	MAEs defined as clinically-driven target lesion revascularization, major amputation of the treated limb, and all-cause death	6, 12, or 24 months